Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06594042
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-10
Brief Title:
Serum Preptin Level and Its Relationship with Bone Mineral Disease in Chronic Kidney Disease Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Serum Preptin Level and Its Relationship with Bone Mineral Disease in Chronic Kidney Disease Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aim of the researchTo identify preptin level and relationship with bone disease in chronic kidney disease patients
Detailed Description:
Preptin is a 34-aminoacid peptide derived from the E-peptide of pro-insulin-like growth factor 2 pro-IGF2 that is co-secreted with insulin and upregulates glucose-mediated insulin secretion High serum preptin levels were described in conditions associated with insulin resistance such as polycystic ovary syndrome and type 2 diabetes mellitus T2M Insulin and also IGF2 are known to be anabolic bone hormones
Preptin stimulates osteoblastic proliferation and increases mineralization in a concentration-independent manner in osteoblast precursor cell Despite being associated with insulin resistance an increased fat mass has beneficial bone effects While the increased mechanical loading favors bone formation adipokines and also pancreatic and gut hormones were also proposed to mediate the relationship between fat and bone The importance of nutritional hormones in maintaining bone mass was thus recognized Insulin has anabolic bone effects and hyperinsulinemia contributes to increased bone mineral density BMD Similar to insulin insulin-like growth factor 1 IGF1 and IGF2 preptin was recently proposed to have anabolic bone activity
End-stage renal disease ESRD patients present with specific bone and mineral metabolism disturbances Chronic kidney disease-associated mineral and bone disorder accounts for increased morbidity and mortality in those patients Biochemical markers known thus far do not effectively predict the complex bone changes that are observed in ESRD patients
Preptin stimulates osteoblastic proliferation and increases mineralization in a concentration-independent manner in osteoblast precursor cell Despite being associated with insulin resistance an increased fat mass has beneficial bone effects While the increased mechanical loading favors bone formation adipokines and also pancreatic and gut hormones were also proposed to mediate the relationship between fat and bone The importance of nutritional hormones in maintaining bone mass was thus recognized Insulin has anabolic bone effects and hyperinsulinemia contributes to increased bone mineral density BMD Similar to insulin insulin-like growth factor 1 IGF1 and IGF2 preptin was recently proposed to have anabolic bone activity
End-stage renal disease ESRD patients present with specific bone and mineral metabolism disturbances Chronic kidney disease-associated mineral and bone disorder accounts for increased morbidity and mortality in those patients Biochemical markers known thus far do not effectively predict the complex bone changes that are observed in ESRD patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None